SecBot SecBot
COURT-RULING ·Filed Apr 13, 2026

VTRS

Viatris Inc
BEARISH
Impact 5/10
Horizonmonths Processed4mo ago CourtCourt Ruling · courtlistener.com
Court ruling (district)
Actionable Insight ▼ Bearish

The narrowing of Mylan's antitrust claims reduces the expected value of the litigation for VTRS. The case continues but with weaker prospects; monitor for summary judgment motions or settlement developments. TEVA benefits from the dismissal of several theories.

DirectionBearish
Confidencemedium
Horizonmonths

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$13.91
T+0 close · Apr 14, 2026 · via day close
Latest settled
+16.97%
T+60 · $16.27
Vs SPY
+8.26%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 14 $13.91entry
  2. T+1 · 7mo ago −0.36%α −1.15% · $13.86
  3. T+5 · 7mo ago +5.89%α +4.51% · $14.73
  4. T+20 · 6mo ago +23.44%α +17.14% · $17.17
  5. T+60 · 4mo ago +16.97%α +8.26% · $16.27
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

The district court partially granted Teva's motion to dismiss Mylan's antitrust complaint, dismissing with prejudice allegations regarding sham citizen petitions, ANDA lawsuits, market shift, copay assistance, and foreign conduct, but allowing claims based on the DAW campaign, exclusionary PBM agreements, and the 2020 reclassification petition to proceed. The ruling significantly narrows Viatris's (Mylan's) antitrust case against Teva, reducing the potential scope of damages.

Court Ruling Details

Ruling Date
Apr 13, 2026
Court
United States District Court for the District of New Jersey
Court Level
District
Judge
Julien Xavier Neals
Case Type
antitrust
Ruling Type
motion to dismiss
Outcome
PARTIAL: mixed ruling, some claims won/lost
Precedent Risk
LOW

Key Facts

  • Court adopted Special Master's R&R, partially granting Teva's motion to dismiss.
  • Antitrust allegations regarding 20mg citizen petitions, 20mg ANDA litigation, market shift, copay assistance, and foreign conduct dismissed with prejudice.
  • Allegations about DAW campaign, exclusionary PBM agreements, and 2020 reclassification petition/lawsuit survive.
  • Lanham Act claim (Count II) and state law claims (Counts III-VI) survive.
  • No damages awarded; case proceeds on a narrower set of theories.
  • Opinion dated April 13, 2026.

Financial Impact

Mylan's antitrust case against Teva survives but with reduced scope; potential treble damages now limited to surviving claims (DAW campaign, PBM agreements, 2020 reclassification). No dollar amount stated in ruling.

legal exposurepotential settlement value

Risk Factors

  • Case may be further narrowed on summary judgment or at trial.
  • Mylan may settle on less favorable terms given reduced claims.
  • Appeal of dismissed claims is unlikely given interlocutory nature of ruling.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
67% bullish (18 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 court opinion.

DocumentAccession Number
COURT-RULING Data (Synthetic)court-15mpe8hi-VTRS

US Market Status

Market Open · Closes in 40m

Subscribe to SecBot

Get Real-Time Court Ruling Intelligence

Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more, parsed and scored by AI.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
⚖ Court Ruling · courtlistener.com Report published Jul 2, 2026